A5113593938- Head and Neck Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Peptidase Inhibition and Analysis
- Lung Cancer Diagnosis and Treatment
- Head and Neck Surgical Oncology
- Brain Metastases and Treatment
- Colorectal and Anal Carcinomas
- Cancer Genomics and Diagnostics
- Salivary Gland Tumors Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Colorectal Cancer Treatments and Studies
- Glioma Diagnosis and Treatment
- Effects of Radiation Exposure
- Tumors and Oncological Cases
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lymphoma Diagnosis and Treatment
- Medical Imaging and Pathology Studies
- Histone Deacetylase Inhibitors Research
- Tryptophan and brain disorders
- Cancer therapeutics and mechanisms
- Cancer Treatment and Pharmacology
- Multiple Myeloma Research and Treatments
Thomas Jefferson University
2014-2025
Thomas Jefferson University Hospital
2010-2023
Sidney Kimmel Cancer Center
2001-2023
Emory University
2006-2015
National University Cancer Institute, Singapore
2015
Memorial Sloan Kettering Cancer Center
2014
The University of Texas MD Anderson Cancer Center
2014
Philadelphia University
2007-2013
Holy Cross Hospital
2008
University Hospitals of Cleveland
2008
Oropharyngeal squamous-cell carcinomas caused by human papillomavirus (HPV) are associated with favorable survival, but the independent prognostic significance of tumor HPV status remains unknown.We performed a retrospective analysis association between and survival among patients stage III or IV oropharyngeal carcinoma who were enrolled in randomized trial comparing accelerated-fractionation radiotherapy (with acceleration means concomitant boost radiotherapy) standard-fractionation...
Purpose Combining cisplatin or cetuximab with radiation improves overall survival (OS) of patients stage III IV head and neck carcinoma (HNC). Cetuximab plus platinum regimens also increase OS in metastatic HNC. The Radiation Therapy Oncology Group launched a phase trial to test the hypothesis that adding radiation-cisplatin platform progression-free (PFS). Patients Methods Eligible HNC were randomly assigned receive without (arm A) B) cetuximab. Acute late reactions scored using Common...
To test the ability of cytoprotectant, amifostine, to reduce chemoradiotherapy-induced esophagitis and evaluate its influence on quality life (QOL) swallowing symptoms.A total 243 patients with stage II IIIA/B non-small-cell lung cancer received induction paclitaxel 225 mg/m(2) intravenously (IV) days 1 22 carboplatin area under curve (AUC) 22, followed by concurrent weekly (50 IV) (AUC 2), hyperfractionated radiation therapy (69.6 Gy at 1.2 bid). Patients were randomly assigned registration...
A multicenter randomized phase II trial to evaluate two treatment strategies in the first-line management of advanced non-small-cell lung cancer (NSCLC) patients with a performance status (PS) 2.Patients were assigned erlotinib 150 mg orally daily until progression or carboplatin (area under curve [AUC] 6) and paclitaxel (200 mg/m(2) day 1 every 3 weeks) for up four cycles. Patients who experienced did not tolerate refused further chemotherapy allowed cross over erlotinib. The primary end...
In CheckMate 227 Part 1, nivolumab plus ipilimumab prolonged overall survival (OS) versus chemotherapy in patients with metastatic NSCLC, regardless of tumor programmed death-ligand 1 (PD-L1) expression. Here, we report post hoc exploratory systemic and intracranial efficacy outcomes safety by baseline brain metastasis status at 5 years' minimum follow-up.Treatment-naive adults stage IV or recurrent NSCLC without EGFR ALK alterations, including asymptomatic treated metastases, were enrolled....
To evaluate the efficacy and toxicity of bortezomib +/- docetaxel as second-line therapy in patients with relapsed or refractory advanced non-small-cell lung cancer (NSCLC).Patients were randomly assigned to 1.5 mg/m2 (arm A) 1.3 plus 75 B). A treatment cycle 21 days comprised four doses on 1, 4, 8, 11, plus, arm B, day 1. Patients could receive unlimited cycles. The primary end point was response rate.A total 155 treated, 80 B. Baseline characteristics comparable. Investigator-assessed...
Abstract BACKGROUND: Bortezomib, an inhibitor of the 26S proteasome and NF‐κB, may have antitumor activity in adenoid cystic carcinoma (ACC). Preclinical studies shown synergy between bortezomib doxorubicin. METHODS: Eligibility criteria included incurable ACC, any number prior therapies but without anthracycline, unidimensionally measurable disease, Eastern Cooperative Oncology Group performance status 0‐2, ejection fraction within normal limits. Patients with stable disease for ≥9 months...
There is a significant need to find biomarkers of response radiotherapy and cetuximab in locally advanced head neck squamous cell carcinoma (HNSCC) that predict altered immunity, thereby enabling personalized treatment.To examine whether the Kirsten rat sarcoma viral oncogene homolog (KRAS)-variant, germline mutation microRNA-binding site KRAS, predictive biomarker immunity setting cisplatin treatment evaluate interaction KRAS-variant with p16 status blood-based transforming growth factor β1...
Abstract Purpose: We hypothesize that the addition of phosphodiesterase-5 inhibitor tadalafil to PD-1 nivolumab, is safe and will augment immune-mediated antitumor responses in previously untreated squamous cell carcinoma head neck (HNSCC). Patients Methods: conducted a two-arm multi-institutional neoadjuvant randomized trial any-stage resectable HNSCC (NCT03238365). were stratified at randomization by human papillomavirus (HPV) status. both arms received nivolumab 240 mg intravenously on...
Linifanib, a potent, selective inhibitor of vascular endothelial growth factor (VEGF) and platelet-derived (PDGF) receptors, has single-agent activity in non-small-cell lung cancer (NSCLC). We evaluated linifanib with carboplatin paclitaxel as first-line therapy advanced nonsquamous NSCLC.
PD-1 blockade represents a promising treatment in patients with head and neck squamous cell carcinoma (HNSCC). We analyzed results of neoadjuvant randomized window-of-opportunity trial nivolumab plus/minus tadalafil to investigate whether immunotherapy-mediated effects vary by site involvement (primary tumor, lymph nodes) determine how radiographic tumor shrinkage correlates pathologic effect. Forty-four enrolled NCT03238365 were treated 240 mg intravenously on days 1 15 or without oral...
9051 Background: Patients (pts) with resectable stage IB (≥4cm)-IIIA non-small-cell lung cancer (NSCLC) derive modest overall survival benefit neoadjuvant or postoperative adjuvant chemotherapy. Neoadjuvant therapy can speed the discovery of promising regimens by using pathologic response as a surrogate for OS. Major (MPR), defined < 10% viable tumor, was strongly associated improved PD-(L)1 checkpoint inhibitors in combination chemotherapy are standard care advanced NSCLC. We hypothesize...
Abstract Purpose: Neoadjuvant chemotherapy for structure preservation (SP) in nasal and paranasal sinus squamous cell carcinoma (NPNSCC) has been described single-institution but not randomized studies. EA3163 was a study investigating whether cytoreductive neoadjuvant would improve SP or overall survival (OS). Patients Methods: with T3/T4a select T4b NPNSCC requiring orbital base of skull (BOS) resection were to surgery (Arm A), versus preceded by docetaxel/cisplatin x3 cycles B). Degree...
External beam irradiation of malignant astrocytoma often provides temporary local tumor control, but dose is limited by potential toxicity to normal brain. Fractionated stereotactic radiotherapy (SRT) additional radiation the with less deposition in adjacent We administered a radiosensitizer, cis-platinum (CDDP), optimize therapeutic index. CDDP (40 mg/m2) was given weekly, SRT once or twice 20 patients. One had partial response, 11 stable disease, and eight progressed despite therapy. Acute...
6583 Background: Despite multimodality standard therapy, patients (pts) with resectable locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) are at high risk for recurrence. Pts pathologic complete response (pCR) or major (MPR) to neoadjuvant chemotherapy have improved overall survival. PD-1 checkpoint inhibitors approved in combination platinum-based 1st-line treatment recurrent/metastatic SCCHN. We hypothesize addition N wkly carboplatin C P will increase pCR rate...
Background The combination of nivolumab and ipilimumab has been approved for the treatment multiple solid tumors. This was a phase I study investigating definitive radioimmunotherapy (RIT) with locally advanced (LA) squamous cell carcinoma head neck (SCCHN). Methods Patients newly diagnosed, stage IVA–IVB SCCHN eligible cisplatin-based chemotherapy received (3 mg/kg every 2 weeks total 17 doses) (1 6 starting prior to radiotherapy. primary endpoint safety RIT. Secondary endpoints included...
<p>Supplementary Appendix</p>
<p>Supplement Figure 1: Waterfall Plots. A: Degree of pathologic treatment response (pTR) at the lymph nodes. B: primary site, stratifed by arm. C: RECIST tumor site (yellow) and nodes (purple), arm.</p>